Krysten L. Jones

Krysten L. Jones

Auto-generated profile, based on publicly available information

Krysten L. Jones

Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
KMKathryn H. Morelli
Kathryn H. Morelli
QWQian Wu
Qian Wu
MGMaya L. Gosztyla
Maya L. Gosztyla
HLHongshuai Liu
Hongshuai Liu
MYMinmin Yao
Minmin Yao
GYGene W. Yeo
Gene W. Yeo
Huntington’s disease (HD) is a fatal, dominantly inherited neurodegenerative disorder caused by CAG trinucleotide expansion in exon 1 of the huntingtin (HTT) gene. Since the reduction of pathogenic mutant HTT messenger RNA is therapeutic, we developed a mutant allele-sensitive CAGEX RNA-targeting CRISPR–Cas13d system (Cas13d–CAGEX) that eliminates toxic CAGEX RNA in fibroblasts derived from patients with HD and induced pluripotent stem cell-derived neurons. We show that intrastriatal delivery of Cas13d–CAGEX via an adeno-associated viral vector selectively reduces mutant HTT mRNA and protein levels in the striatum of heterozygous zQ175 mice, a model of HD. This also led to improved motor coordination, attenuated striatal atrophy and reduction of mutant HTT protein aggregates. These phenotypic improvements lasted for at least eight months without adverse effects and with minimal off-target transcriptomic effects. Taken together, we demonstrate proof of principle of an RNA-targeting CRISPR–Cas13d system as a therapeutic approach for HD, a strategy with implications for the treatment of other dominantly inherited disorders.

29 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
KMKathryn H. Morelli
Kathryn H. Morelli
WJWenhao Jin
Wenhao Jin
SSShashank Shathe
Shashank Shathe
AMAssael A. Madrigal
Assael A. Madrigal
KJKrysten L. Jones
Krysten L. Jones
GYGene W. Yeo
Gene W. Yeo
Myotonic dystrophy type 1 (DM1) is a multisystem, autosomal-dominant inherited disorder caused by CTG microsatellite repeat expansions (MREs) in the 3′ untranslated region of the dystrophia myotonica-protein kinase ( DMPK ) gene. Despite its prominence as the most common adult-onset muscular dystrophy, patients with congenital to juvenile-onset forms of DM1 can present with debilitating neurocognitive symptoms along the autism spectrum, characteristic of possible in utero cortical defects. However, the molecular mechanism by which CTG MREs lead to these developmental central nervous system (CNS) manifestations is unknown. Here, we showed that CUG foci found early in the maturation of three-dimensional (3D) cortical organoids from DM1 patient–derived induced pluripotent stem cells (iPSCs) cause hyperphosphorylation of CUGBP Elav-like family member 2 (CELF2) protein. Integrative single-cell RNA sequencing and enhanced cross-linking and immunoprecipitation (eCLIP) analysis revealed that reduced CELF2 protein–RNA substrate interactions results in misregulation of genes critical for excitatory synaptic signaling in glutamatergic neurons, including key components of the methyl-CpG binding protein 2 (MECP2) pathway. Comparisons to MECP2 (y/−) cortical organoids revealed convergent molecular and cellular defects such as glutamate toxicity and neuronal loss. Our findings provide evidence suggesting that early-onset DM1 might involve neurodevelopmental disorder-associated pathways and identify N -methyl- d -aspartic acid (NMDA) antagonists as potential treatment avenues for neuronal defects in DM1.